3/7
08:13 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/5
09:33 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at Morgan Stanley from $49.00 to $45.00. They now have an "overweight" rating on the stock.
Medium
Report
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at Morgan Stanley from $49.00 to $45.00. They now have an "overweight" rating on the stock.
3/5
08:00 am
sln
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Medium
Report
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
3/4
01:23 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at BMO Capital Markets from $67.00 to $25.00. They now have an "outperform" rating on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at BMO Capital Markets from $67.00 to $25.00. They now have an "outperform" rating on the stock.
3/4
09:54 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $6.00 to $4.00. They now have a "sell" rating on the stock.
Medium
Report
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $6.00 to $4.00. They now have a "sell" rating on the stock.
3/1
07:07 pm
sln
Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
2/27
08:17 am
sln
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
2/27
07:30 am
sln
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
2/26
05:31 pm
sln
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
Low
Report
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
2/26
05:31 pm
sln
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
Low
Report
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
2/13
08:35 am
sln
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 [Yahoo! Finance]
Low
Report
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 [Yahoo! Finance]
2/13
08:00 am
sln
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Low
Report
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
2/11
07:27 am
sln
Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "sell" rating and a $6.00 price target on the stock.
High
Report
Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "sell" rating and a $6.00 price target on the stock.
1/29
01:21 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Neutral
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.